Efficace, Fabio
Boccadoro, Mario
Palumbo, Antonio
Petrucci, Maria Teresa
Cottone, Francesco
Cannella, Laura
Zamagni, Elena
Niscola, Pasquale
Kyriakou, Charalampia
Caravita, Tommaso
Offidani, Massimo
Mandelli, Franco
Cavo, Michele
Funding for this research was provided by:
Amgen
GIMEMA
Article History
Received: 14 August 2017
Accepted: 4 June 2018
First Online: 18 June 2018
Ethics approval and consent to participate
: This study will be conducted in accordance with the principles of Good Clinical Practice and the protocol was approved by the University ‘Sapienza’ Ethics Committee in July 2017.
: Fabio Efficace: Consultancy for Seattle Genetics, TEVA, Amgen and Incyte; Research funding: Lundbeck, TEVA and Amgen.Tommaso Caravita: Advisory Board for Celgene, JJ, Amgen, Takeda, BMS; Travel grant from Celgene, JJ, Amgen; Funding from Celgene; Speaker for Siemens.Maria Teresa Petrucci: Honoraria for Celgene, Janssen-Cilag, Takeda, Amgen and BMS.Michele Cavo: Honoraria, Advisory Boards and Speaker’s Bureau for Janssen, Celgene, Bristol-Myers Squibb, and Takeda; Honoraria and Advisory Boards for Amgen.Antonio Palumbo: is currently a Takeda employee, data reported here have been generated during his previous Investigator role, and are not reflecting any Takeda’s position; Ownership interests (including stock options): Takeda; Honoraria and Consultancy for Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, Sanofi Aventis and Merck; Research funding from: Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, Sanofi Aventis, Merck and Binding Site; Speakers’ Bureau: Bristol-Myers Squibb.Elena Zamagni: honoraria and member of advisory board for Celgene, Janssen, BMS, Amgen and Takeda.Other authors have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.